This single paragraph provides significant insight into internal priorities. It confirms that, as of 2025, Health officials were actively developing options to revise statutory price-reduction mechanisms to align them with changes to the NMFG. The nature of these changes, however, remains protected via redactions. The justifications for the redactions provide useful insights.
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News
